Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Monday 05 November, 2018

Marinomed Biotech Ag

EANS-Adhoc: Marinomed Biotech AG / Marinomed intends to conduct an IPO on the Vienna Stock Exchange

PR Newswire/euro adhoc/

EANS-Adhoc: Marinomed Biotech AG / Marinomed intends to conduct an IPO on the
Vienna Stock Exchange

--------------------------------------------------------------------------------
  Disclosed inside information pursuant to article 17 Market Abuse Regulation
  (MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution.
  The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

Capital Measures
05.11.2018

Vienna - November 5, 2018. In implementing its financing options, Marinomed
Biotech AG intends to conduct an initial public offering (IPO) and a listing of
its shares on the Vienna Stock Exchange and has mandated Erste Group Bank AG and
Kempen & Co N.V. as Joint Global Coordinators and Joint Bookrunners and
goetzpartners securities Limited as Co-Lead Manager for the planned transaction.

In the course of the planned IPO, new shares shall be offered to retail and
institutional investors in Austria in a public offering and to international
institutional investors in private placements. It is intended to apply for
listing of the shares on the Official Market (Amtlicher Handel) in the prime
market segment of the Vienna Stock Exchange. The planned transaction is intended
to meet the requirements of a qualified public offering in accordance with the
terms and conditions of the convertible bonds issued in 2017 that are admitted
to trading on the Third Market of the Vienna Stock Exchange. Following the
completion of a qualified public offering, convertible bondholders are entitled
to convert their bonds into new shares in Marinomed Biotech AG in accordance
with the terms and conditions of the convertible bond. The volume and the timing
of a possible transaction depend on the prevailing market environment.

About Marinomed Biotech AG
Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the
development of innovative products derived from patent protected technology
platforms to treat respiratory and ophthalmic conditions. The Carragelose®
platform comprises innovative patent protected products targeting viral
infections of the respiratory tract. Carragelose® is used in nasal sprays,
throat sprays and lozenges, which are sold in more than 30 countries around the
world in collaboration with international partners.The Marinosolv® technology
platform increases the efficacy of hardly soluble compounds for the treatment of
sensitive tissues such as the eyes and nose. Further information is available at
www.marinomed.com.

Disclaimer
This announcement does not constitute an offer to purchase securities or
solicitation of an offer to purchase securities in the United States of America,
Germany, Austria or other jurisdictions. The shares (the "Shares") of Marinomed
Biotech AG (the "Company") may only be sold or offered for sale after prior
registration in the United States of America upon or without prior registration
by virtue of an exemption from the registration requirement under the provisions
of the US Securities Act of 1933, as amended. The Company does not intend to
fully or partially register any offer of Shares in the United States or to make
any public offering of Shares in the United States. Any public offer of
securities of the Company in Austria shall be made solely by, and on the basis
of, a prospectus for securities to be prepared and published in accordance with
the provisions of the Capital Markets Act (Kapitalmarktgesetz) (including any
supplements thereto). An investment decision regarding publicly offered
securities of the Company should only be made on the basis of such a prospectus.
Any purchase orders relating to securities of the Company received prior to the
commencement of a public offering will be rejected. In the event of a public
offering of securities of the Company in Austria, a prospectus will be prepared
in accordance with the provisions of the Capital Markets Act
(Kapitalmarktgesetz), which will be published immediately upon approval by the
Financial Market Authority (Finanzmarktaufsicht) and be available free of charge
at Marinomed Biotech AG, Veterinärplatz 1, A-1210 Vienna, or on the website of
Marinomed Biotech AG.






Further inquiry note:
Eva Prieschl-Grassauer, PhD
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria
Tel.: +43 (0)1 250 77 4460
E-mail: [email protected]
http://www.marinomed.com

Roland Mayrl
Managing Partner, Metrum Communications
Prinz-Eugen-Straße 80/16, 1040 Vienna, Austria
Tel.: +43 (0) 1 504 69 87 331
E-mail: [email protected]
http://www.metrum.at


end of announcement                         euro adhoc
--------------------------------------------------------------------------------



issuer:       Marinomed Biotech AG
              Veterinärplatz 1
              A-1210 Wien
phone:        0043250774460
FAX:          0043250774493
mail:         [email protected]
WWW:          www.marinomed.com
ISIN:         AT0000A1WD52
indexes:      
stockmarkets: Wien
language:     English
                
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication.

a d v e r t i s e m e n t